JPM vs SLM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
SLM presents a stark contradiction between explosive growth and deteriorating financial health, highlighted by a weak Piotroski F-Score of 2/9. While the stock is fundamentally undervalued with a P/E of 6.54 and trades below its Graham Number of $29.32, the low health score and bearish technical trend (0/100) suggest a potential value trap. Exceptional YoY earnings growth of 126.20% is offset by a high Debt/Equity ratio of 2.40 and a poor recent track record of earnings surprises. The discrepancy between the current price and the growth-based intrinsic value ($102.07) reflects significant market skepticism regarding the sustainability of its current trajectory.
Compare Another Pair
Related Comparisons
JPM vs SLM: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and SLM Corporation (SLM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.